Level-KSachet

Level-K is a potassium-binding (cation-exchange) resin used for the treatment of hyperkalemia (elevated blood potassium).

Established / FDA-approved use

• Treatment of hyperkalemia in patients who need to lower elevated serum potassium levels, most commonly in chronic kidney disease, when dietary/medication changes alone are insufficient.

Guideline-supported / adjunct use

• Used as an adjunct to standard emergency measures (e.g., calcium gluconate, insulin/glucose, dialysis) in acute, severe hyperkalemia — Level-K alone is not appropriate as sole therapy for a life-threatening potassium elevation because its onset of action is not immediate.
• Used for short-term or intermittent management of chronic/recurrent hyperkalemia, such as in patients on renin-angiotensin system inhibitors or with end-stage renal disease between dialysis sessions.

It does not treat the underlying cause of hyperkalemia and is not intended for routine long-term use given its gastrointestinal and sodium-load risks.

Each unit of Sodium Polystyrene Sulfonate contains the active ingredient Sodium Polystyrene Sulfonate (a sulfonated polystyrene cation-exchange resin in the sodium form).

Locally available presentations typically include:

• Powder for oral/rectal suspension
• Ready-to-use oral suspension

Strength is generally expressed as grams of resin per dose (e.g., 15 g sachets/scoops), as this is a resin rather than a conventional small-molecule drug measured in milligrams.

Level-K is a non-absorbed, sodium-form cation-exchange resin. When it passes through the gastrointestinal tract, it releases sodium ions and binds potassium ions, which are then eliminated from the body in the stool.

It is supplied as a powder that is suspended in water or a suitable vehicle (never sorbitol) shortly before use, and can be given orally or, less commonly, as a retention enema. Level-K has been used clinically for decades as a means of lowering elevated serum potassium.

Potassium-binding cation-exchange resin (antihyperkalemic agent) — Level-K

Mechanism of action

Sodium Polystyrene Sulfonate works in the lumen of the gastrointestinal tract, mainly the colon, by exchanging sodium ions on the resin for potassium ions present in the gut. The potassium is then bound to the resin and excreted in the feces, lowering total body and serum potassium.

Pharmacokinetics

Sodium Polystyrene Sulfonate is not systemically absorbed; its action is confined to the GI tract. The onset of potassium-lowering effect is gradual — typically several hours to a day or more — rather than immediate, which is why it is unsuitable as sole treatment for a medical emergency. Each gram of resin can bind approximately 1 mEq of potassium under ideal conditions, though actual clinical exchange is variable and also removes some calcium and magnesium.

• Level-K powder should be suspended in water or a small amount of syrup immediately or shortly before administration; do not use sorbitol as the suspending vehicle.
• Do not heat the suspension, as this may reduce the resin's exchange capacity.
• For oral use, the suspension may be sipped or given by nasogastric tube if needed.
• For rectal administration, the warm suspension is given as a retention enema and should be retained for as long as possible (ideally several hours) before evacuation, followed by a cleansing enema if instructed by the physician.
• Separate administration of Level-K from other oral medicines by at least a few hours where possible, as it can reduce absorption of some co-administered drugs (see Interactions).
• Only freshly prepared suspensions should be used; discard suspension not used within 24 hours.

• Sorbitol: Concomitant use of sorbitol with Level-K has been associated with intestinal necrosis, which may be fatal. Sorbitol-containing formulations/vehicles should be avoided.
• Antacids and laxatives containing magnesium or aluminum: Should not be given with Level-K, as they can reduce its potassium-binding capacity and, in the case of magnesium- or aluminum-containing agents, increase the risk of systemic alkalosis or GI concretions.
• Digoxin: Hypokalemia resulting from Level-K therapy can potentiate digitalis toxicity (arrhythmias), even when digoxin levels are within the normal range.
• Lithium and levothyroxine (thyroxine): Level-K may bind these drugs in the gut and reduce their absorption; separate dosing times where co-administration is necessary.

The following side effects have been reported with Level-K.

Common

• Nausea, vomiting, anorexia, gastric irritation
• Constipation or, less often, diarrhea

Electrolyte-related

• Hypokalemia (from overcorrection), hypocalcemia, hypomagnesemia, and sodium retention (see Precautions and Warnings for monitoring guidance).

Serious (uncommon but important)

• Intestinal necrosis, fecal impaction, gastrointestinal concretions/bezoars, ischemic colitis, and bowel perforation — see Precautions and Warnings.

Pregnancy: Data on the use of Level-K in pregnancy are limited. It should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; use only under a physician's direction.

Lactation: It is not known whether Level-K or its exchanged ions are excreted into human breast milk in a clinically significant way. Caution is advised, and a physician should be consulted before use while breastfeeding.

Intestinal necrosis

Cases of intestinal necrosis, which may be fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported with Level-K, particularly when co-administered with sorbitol and in patients with impaired bowel motility or a history of bowel surgery. Avoid sorbitol-containing formulations and discontinue Level-K if severe constipation, abdominal pain, distension, rectal bleeding, or worsening symptoms occur.

Electrolyte disturbances

Level-K can cause hypokalemia (with overcorrection), hypocalcemia, and hypomagnesemia. Serum potassium, calcium, magnesium, and sodium should be monitored regularly, particularly with prolonged use or frequent dosing.

Sodium load

Because Level-K works by exchanging sodium for potassium, each gram of resin can deliver a clinically significant sodium load. Use with caution in patients with heart failure, hypertension, significant edema, or renal impairment.

Bowel function

Confirm normal bowel function before starting therapy and avoid use in patients at risk of gastrointestinal obstruction. Constipation is common; ensure adequate bowel movements during treatment.

Not for emergency use alone

The onset of action of Level-K is not immediate. It should not be relied upon as the sole treatment for severe or life-threatening hyperkalemia requiring emergent correction (e.g., calcium gluconate, insulin with glucose, or dialysis).

Overdosage of Level-K can cause significant electrolyte disturbances, primarily hypokalemia, along with hypocalcemia and hypomagnesemia, which may present as muscle weakness, confusion, abnormal heart rhythms, or, in severe cases, paralysis or respiratory difficulty.

If an overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Treatment should be supervised by a physician and generally involves stopping the drug and correcting electrolyte imbalances under medical monitoring; do not attempt to manage a suspected overdose with home remedies.

Store at room temperature, generally 20°C to 25°C (68°F to 77°F), with brief excursions up to 30°C permitted; protect from excess moisture. Keep out of reach of children. If a suspension is prepared at home or by a pharmacy, use it within 24 hours and discard any unused portion; do not heat the suspension.

• Renal impairment: Level-K is frequently used in patients with reduced kidney function, but the associated sodium load requires caution and monitoring, especially with fluid overload or hypertension.
• Hepatic impairment: No specific dosage guidance is established; use with routine clinical caution.
• Elderly patients: May be at higher risk of constipation and fecal impaction; ensure adequate bowel function and hydration, and monitor closely.
• Pediatric patients / neonates: See Pediatric Uses and Contraindications — oral use is contraindicated in neonates, and safety/efficacy in children generally has not been formally established.

Level-K is generally used for the shortest duration needed to correct hyperkalemia or to manage recurrent episodes intermittently, alongside treatment of the underlying cause (e.g., dietary potassium restriction, adjustment of interacting medications, dialysis schedule). It is not intended as an indefinite, uninterrupted daily therapy given the cumulative risks of sodium load, electrolyte depletion, and gastrointestinal complications with prolonged use. Duration should be determined and periodically reassessed by the treating physician based on serum potassium trends.

Level-K powder is not reconstituted in the sterile-injectable sense but must be suspended immediately or shortly before use: mix the prescribed dose of powder in water or a small amount of a non-sorbitol syrup for oral use, or in warm water for a retention enema. Do not heat the suspension. Use freshly prepared suspension only; discard any portion not used within 24 hours.

Cation-exchange resin; Antihyperkalemic (potassium-lowering) agent — Sodium Polystyrene Sulfonate

Sodium Polystyrene Sulfonate acts locally within the gastrointestinal tract. As the resin passes through the intestines (predominantly the large intestine), it releases sodium ions from its structure in exchange for potassium ions present in the gut lumen. The potassium-bound resin is then excreted in the stool, resulting in a net reduction of total body and serum potassium. Because this exchange occurs within the gut rather than through systemic absorption, the onset of the potassium-lowering effect is gradual rather than immediate.

C

The safety and efficacy of Level-K in pediatric patients have not been firmly established in controlled trials, and dosing is generally extrapolated and individualized on a weight/potassium-binding basis under close physician supervision.

Oral administration of Level-K is contraindicated in neonates, particularly premature or low-birth-weight infants, because of an increased risk of intestinal necrosis and other serious gastrointestinal adverse events, especially when given with sorbitol-containing formulations. Rectal use in infants and children, when used, requires careful dosing and monitoring for constipation, impaction, and bowel injury.